Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Profit After Tax (2018 - 2025)

Black Diamond Therapeutics' Profit After Tax history spans 6 years, with the latest figure at -$15.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 5.44% year-over-year to -$15.1 million; the TTM value through Dec 2025 reached $22.4 million, up 132.1%, while the annual FY2025 figure was $22.4 million, 132.1% up from the prior year.
  • Profit After Tax reached -$15.1 million in Q4 2025 per BDTX's latest filing, down from -$8.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $56.5 million in Q1 2025 to a low of -$35.1 million in Q3 2021.
  • Average Profit After Tax over 3 years is -$13.4 million, with a median of -$16.0 million recorded in 2024.
  • Peak YoY movement for Profit After Tax: crashed 149.49% in 2021, then skyrocketed 410.24% in 2025.
  • A 3-year view of Profit After Tax shows it stood at -$35.1 million in 2021, then surged by 54.43% to -$16.0 million in 2024, then rose by 5.44% to -$15.1 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Profit After Tax are -$15.1 million (Q4 2025), -$8.5 million (Q3 2025), and -$10.6 million (Q2 2025).